Upgrades/Downgrades
Updated: 19-May-26 16:30 ET
| Upgrades | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| StubHub Holdings | STUB | Guggenheim | Neutral » Buy | $12.50 | |
| Progyny | PGNY | Canaccord Genuity | Hold » Buy | $30 | |
| Jazz Pharma | JAZZ | UBS | Neutral » Buy | $307 | |
| Credicorp LTD | BAP | HSBC Securities | Hold » Buy | $350 | |
| Assured Guaranty | AGO | UBS | Neutral » Buy | $94 | |
| American Tower | AMT | Bernstein | Mkt Perform » Outperform | $207 | |
|
|
|||||
| Downgrades | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Korea Electric Power Corp | KEP | Morgan Stanley | Equal-Weight » Underweight | ||
| Hanover Insurance | THG | BMO Capital Markets | Outperform » Market Perform | $203 | |
| James River Group | JRVR | UBS | Buy » Neutral | $4.75 | |
| Fortinet | FTNT | DZ Bank | Buy » Hold | $125 | |
| CrowdStrike | CRWD | DZ Bank | Buy » Sell | $500 | |
| Biofrontera Inc. | BFRI | The Benchmark Company | Buy » Speculative Buy | $3 | |
| Principal Fincl | PFG | Raymond James | Strong Buy » Outperform | $111 | |
|
|
|||||
| Coverage Initiated | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| X-Energy | XE | Wolfe Research | Peer Perform | ||
| X-Energy | XE | Morgan Stanley | Overweight | $41 | |
| X-Energy | XE | JP Morgan | Overweight | $38 | |
| X-Energy | XE | UBS | Buy | $40 | |
| X-Energy | XE | TD Cowen | Buy | $35 | |
| X-Energy | XE | Guggenheim | Buy | $57 | |
| X-Energy | XE | Jefferies | Hold | $28 | |
| Tyra Biosciences | TYRA | Wolfe Research | Peer Perform | ||
| Oklo Inc. | OKLO | Wolfe Research | Peer Perform | ||
| NeOnc Technologies Holdings | NTHI | Alliance Global Partners | Buy | $13 | |
| Mirum Pharmaceuticals | MIRM | Wolfe Research | Outperform | $145 | |
| Ionis Pharma | IONS | Citigroup | Buy | $115 | |
| Interface | TILE | The Benchmark Company | Buy | $36 | |
| Cytokinetics | CYTK | Citigroup | Buy | $99 | |
| CytomX Therapeutics | CTMX | Wolfe Research | Outperform | $6 | |
| Corpay | CPAY | Loop Capital | Buy | $406 | |
| CG Oncology | CGON | Wolfe Research | Peer Perform | ||
| BridgeBio Pharma | BBIO | Citigroup | Neutral | $82 | |
| BioMarin Pharmaceutical | BMRN | Citigroup | Buy | $75 | |
| Ascendis Pharma | ASND | Citigroup | Buy | $355 | |
| Alnylam Pharma | ALNY | Citigroup | Buy | $380 | |
|
|
|||||
| Coverage Resumed | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Fate Therapeutics | FATE | Jefferies | Buy | ||
| Zeta Global | ZETA | BofA Securities | Buy | $24 | |
| Rapport Therapeutics | RAPP | Truist | Buy | $56 | |
| Pilgrim's Pride | PPC | UBS | Neutral | $30 | |
| Lightspeed | LSPD | BofA Securities | Underperform | $10 | |
|
|
|||||
| Coverage Reiterated/Price Tgt Changed* | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Block | XYZ | Canaccord Genuity | Buy | $80 » $85 | |
| Dell | DELL | Evercore ISI | Outperform | $240 » $270 | |
| Texas Instruments | TXN | Mizuho | Neutral | $255 » $300 | |
| Harley-Davidson | HOG | Morgan Stanley | Underweight | $12 » $15 | |
|
|
|||||
| (a) Brokerage firm initiating coverage participated in underwriting the recent IPO. |
| (b) Brokerage firm resumes coverage. |
| (c) Brokerage firm participated in the secondary offering. |
| * This list of reiterations/target changes is not comprehensive. |